Individualized insulin strategies may improve glycemic control in pediatric T1DM with exogenous insulin antibody syndromeCan personalized insulin plans help kids with a rare, stubborn form of diabetes?

Frontiers in Medicine Published April 5, 2026 DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider individualized insulin optimization for pediatric T1DM with EIAS; MMF may be transiently helpful in refractory cases.

This retrospective case series described clinical characteristics, diagnostic strategies, and therapeutic outcomes in 5 pediatric patients with type 1 diabetes mellitus complicated by exogenous insulin antibody syndrome (EIAS), representing 0.4% of 1,245 T1DM patients evaluated at a single center. Individualized treatment strategies included ultra-rapid insulin with closed-loop pump, regular insulin every 4 hours, switching from pump to multiple daily injections, aspart plus glargine, and mycophenolate mofetil (MMF) for refractory cases. No comparator group was reported.

Regarding glycemic outcomes, individualized insulin optimization improved time in range (TIR) to >70% in 4 of the 5 patients. In the single refractory case treated with MMF, TIR improved to >70% and time below range (TBR) was 30% after 3 months of treatment. However, glycemic instability recurred rapidly within 4 weeks after MMF discontinuation. The study did not report specific effect sizes, p-values, or confidence intervals for these outcomes.

Safety and tolerability data were not reported. Key limitations include the observational nature of the study, the very small sample size (n=5), the absence of a control group, and lack of blinding. The authors note that continuous glucose monitoring metrics (TIR, TBR, coefficient of variation) are essential for assessment in this population, as HbA1c may not reflect glycemic variability. For clinical practice, this evidence suggests that individualized insulin optimization may improve TIR in most pediatric patients with T1DM and EIAS, while MMF may represent a potential option for refractory cases, though its effect appears transient upon discontinuation. Causal inferences cannot be drawn from this design, and findings should be considered hypothesis-generating.

Imagine your child has type 1 diabetes, but on top of that, their immune system starts attacking the very insulin they need to survive. This rare and frustrating condition, called exogenous insulin antibody syndrome (EIAS), makes blood sugar wildly unpredictable. Doctors at one center looked back at how they managed five children facing this double challenge. They tried different, highly personalized strategies for each child, like switching insulin types, changing how it was delivered, or adding a medication that calms the immune system. For four of the five kids, these tailored approaches helped them spend more than 70% of their time in a healthy blood sugar range. The fifth child, whose case was more stubborn, saw improvement with the immune-calming drug, but their blood sugar became unstable again within a month of stopping it. It’s crucial to remember this is a report on just five children from one hospital, with no comparison group. The findings don’t prove what caused the improvements, but they offer a detailed, real-world look at what doctors tried when standard care wasn't enough. They highlight that for these rare cases, continuous glucose monitors are essential tools, as the usual A1c test can miss dangerous swings. This work points to questions for future, more rigorous studies to answer.

What this means for you:

For a rare diabetes complication in kids, personalized insulin plans showed promise in a tiny, early study.

Study Details

Study typeCohort

EvidenceLevel 3

PublishedMar 2026

View Original Abstract ↓

ObjectiveThis study investigates the clinical characteristics, diagnostic strategies, and therapeutic outcomes of individualized treatment for children with type 1 diabetes mellitus (T1DM) complicated by exogenous insulin antibody syndrome (EIAS).MethodsA retrospective case series study was conducted on five pediatric patients diagnosed with T1DM+EIAS at a single center between January 2016 and January 2026. Among 1,245 T1DM patients evaluated, 5 (0.4%) met EIAS diagnostic criteria. Data included demographics, clinical manifestations, laboratory findings (insulin antibodies [IA], C-peptide, continuous glucose monitoring [CGM]), treatment regimens, and outcomes. Longitudinal autoantibody profiles, thyroid function, immune parameters, and cytokines were assessed at four time points. A narrative review of published EIAS cases was conducted following PRISMA guidelines.ResultsCase 1 achieved glycemic stability using ultra-rapid insulin with closed-loop pump (6-hour active insulin duration). Case 2, a 1-year-old infant, required regular insulin every 4 hours (six doses daily). Case 3 switched from pump to conventional multiple daily injections (MDI) with 4–6 daily injections. Case 4 used 4–6 daily aspart doses plus once-daily glargine. All four achieved TIR >70%. Case 5, with refractory disease and IA titer of 33.40 COI, received mycophenolate mofetil (MMF) 600–1,000 mg/m²/day. After 3 months, TIR improved to >70%, TBR 30%. MMF discontinuation resulted in rapid recurrence of instability within 4 weeks.ConclusionEIAS is a rare cause of severe glycemic dysregulation in pediatric T1DM. CGM metrics (TIR, TBR, CV) are essential for assessment, as HbA1c may not reflect glycemic variability. Individualized insulin optimization improves TIR in most patients. For refractory cases, MMF may offer a potential therapeutic option. Due to the observational nature, small sample size (n=5), absence of a control group, and lack of blinding, these findings should be considered hypothesis-generating. Causal inferences cannot be drawn, and the results require validation in prospective, multicenter, controlled studies.

Individualized insulin strategies may improve glycemic control in pediatric T1DM with exogenous insulin antibody syndromeCan personalized insulin plans help kids with a rare, stubborn form of diabetes?

Study Details

Thiazolidinediones show lower hepatocellular carcinoma risk than DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas in this network meta-analysis

New analysis links diabetes drugs to liver outcomes in millions of patients

Clinical research that matters. Delivered to your inbox.

Individualized insulin strategies may improve glycemic control in pediatric T1DM with exogenous insulin antibody syndromeCan personalized insulin plans help kids with a rare, stubborn form of diabetes?

More on Type 1 Diabetes

Study Details

Thiazolidinediones show lower hepatocellular carcinoma risk than DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas in this network meta-analysis

New analysis links diabetes drugs to liver outcomes in millions of patients

Clinical research that matters. Delivered to your inbox.

Related in Diabetes & Endocrinology

From Other Specialties